Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06578559
Title Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET)
Acronym BRICKET
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST